Monopar Therapeutics (NASDAQ:MNPR) Posts Earnings Results, Misses Estimates By $1.87 EPS

Monopar Therapeutics (NASDAQ:MNPR) released its quarterly earnings data on Monday. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($0.36) by ($1.87), Zacks reports.

Monopar Therapeutics Stock Down 8.2 %

Shares of MNPR traded down $2.98 on Tuesday, hitting $33.43. 36,875 shares of the stock traded hands, compared to its average volume of 51,198. The firm has a market capitalization of $203.99 million, a P/E ratio of -16.97 and a beta of 1.18. Monopar Therapeutics has a 1 year low of $1.72 and a 1 year high of $54.30. The stock’s 50 day moving average is $38.48 and its two-hundred day moving average is $24.33.

Wall Street Analyst Weigh In

Several brokerages have issued reports on MNPR. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Monopar Therapeutics in a report on Tuesday. Piper Sandler reaffirmed an “overweight” rating and issued a $76.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, March 19th.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.